OM
CGON icon

Opaleye Management’s CG Oncology CGON Stock Holding History

Opaleye Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Sell
17,789
-77,011
-81% -$5.03M 0.11% 51
2026
Q1 		$6.42M Sell
94,800
-315,200
-77% -$17.9M 0.85% 27
2025
Q4 		$17M Hold
410,000
– – 2.25% 10
2025
Q3 		$16.5M Buy
410,000
+144,000
+54% +$4.19M 2.33% 10
2025
Q2 		$6.92M Buy
266,000
+102,012
+62% +$2.46M 1.4% 15
2025
Q1 		$4.02M Buy
+163,988
New +$4.61M 0.89% 25

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Opaleye Management's CGON Position: Q2 2026 in Review

Opaleye Management reduced its CG Oncology (CGON) stake by 81% in Q2 2026, selling an estimated $5.03M and leaving 17,789 shares worth $1.26M. The position accounts for 0.11% of the portfolio, ranked #51.

Opaleye Management first reported a position in CGON in Q1 2025 and has held it in 6 quarters since. The position peaked at $17M in Q4 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Opaleye Management held 17,789 shares of CG Oncology worth $1.26M as of Q2 2026.
  • Opaleye Management sold 77,011 CG Oncology shares in Q2 2026, an estimated $5.03M.
  • CG Oncology made up 0.11% of Opaleye Management's portfolio in Q2 2026, its #51 holding.
  • Opaleye Management first reported a position in CG Oncology in Q1 2025 and has held it in 6 quarters since.
  • Opaleye Management's CG Oncology position peaked at $17M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.